<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JVMS</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Veterinary Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0916-7250</issn>
      <issn pub-type="epub">1347-7439</issn>
      <publisher>
        <publisher-name>The Japanese Society of Veterinary Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24292246</article-id>
      <article-id pub-id-type="pmc">4064139</article-id>
      <article-id pub-id-type="publisher-id">13-0156</article-id>
      <article-id pub-id-type="doi">10.1292/jvms.13-0156</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Internal Medicine</subject>
          <subj-group>
            <subject>Note</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations
of <bold><italic>c-KIT</italic></bold> Exon 11</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>NAKANO</surname>
            <given-names>Yuko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KOBAYASHI</surname>
            <given-names>Tetsuya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>OSHIMA</surname>
            <given-names>Fukiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>FUKAZAWA</surname>
            <given-names>Eri</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>YAMAGAMI</surname>
            <given-names>Tetsushi</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SHIRAISHI</surname>
            <given-names>Yozo</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>TAKANOSU</surname>
            <given-names>Masamine</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>*</sup>
          </xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Japan Small Animal Cancer Center, 2&#x2013;27&#x2013;4 Nakatomi-minami,
Tokorozawa, Saitama 359&#x2013;0003, Japan</aff>
        <aff id="aff2"><label>2)</label>Division of Clinical Epidemiology, Research Center for
Medical Science, Jikei University School of Medicine, 3&#x2013;25&#x2013;8 Nishi-Shinbashi, Minato-Ku,
Tokyo 105&#x2013;8461, Japan</aff>
        <aff id="aff3"><label>3)</label>Japan Small Animal Medical Center, 2&#x2013;27&#x2013;4 Nakatomi-minami,
Tokorozawa, Saitama 359&#x2013;0003, Japan</aff>
        <aff id="aff4"><label>4)</label>Nasunogahara Animal Clinic, 2&#x2013;3574&#x2013;98 Asaka, Ohtawara,
Tochigi 324&#x2013;0043, Japan</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Takanosu, M., Nasunogahara Animal
Clinic, 2&#x2013;3574&#x2013;98 Asaka, Ohtawara, Tochigi 324&#x2013;0043, Japan. e-mail: <email xlink:href="volkerhall@me.com">volkerhall@me.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <volume>76</volume>
      <issue>4</issue>
      <fpage>545</fpage>
      <lpage>548</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>3</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2014 The Japanese Society of Veterinary Science</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>In 2 individual cases of
canine mast cell tumors, we identified 2 novel <italic>c-KIT</italic> mutations in exon
11: a 9-base pair (bp) deletion (c.1663-1671del) and a point mutation (c.1676T&gt;A). The
9-bp deletion mutation caused a loss of 3 amino acids, corresponding to
p.Gln555_Lys557del, and the point mutation resulted in the substitution of valine by
aspartic acid (p.Val559Asp) in the juxtamembrane domain of the protein. Imatinib mesylate,
a therapeutic agent for canine mast cell tumors, was used to treat both tumors. Complete
remission was achieved at 33 and 14 days after administration, respectively. However, in
both cases, the therapeutic response subsequently tapered with the duration of remission
lasting 66 and 255 days, respectively. Although these 2 novel <italic>c-KIT</italic>
mutations in exon 11 were not confirmed to be gain-of-function mutations, a further study
may help clarify relevance between mutations identified in this report and
responsiveness.</p>
      </abstract>
      <kwd-group>
        <kwd>canine</kwd>
        <kwd>
          <italic>c-KIT</italic>
        </kwd>
        <kwd>imatinib mesylate</kwd>
        <kwd>mast cell tumor</kwd>
        <kwd>mutation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>The <italic>c-KIT</italic> gene encodes a transmembrane type III receptor tyrosine kinase.
Gain-of-function mutations in this gene have been identified in canine mast cell tumors [<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r8" ref-type="bibr">8</xref>]. Although most
exon 11 mutations identified thus far are internal tandem duplications (ITDs), other types,
such as point mutations, deletions and insertions, have also been reported [<xref rid="r8" ref-type="bibr">8</xref>]. <italic>In vitro</italic>, a part of the mutations
result in independent ligand-mediated constitutive phosphorylation of KIT and downstream
signal transduction, which may result in the development and/or proliferation of certain
canine mast cell tumors. Imatinib mesylate is a small-molecule tyrosine kinase inhibitor,
which binds to an adenosine triphosphate-binding site on BCR-ABL, KIT, PDGF-R and ABL
protein-tyrosine kinase, thus preventing downstream signaling. In humans, this drug has been
successfully used as a therapeutic agent for Philadelphia-positive chronic myeloid leukemia
and gastrointestinal stromal tumor carrying a <italic>c-KIT</italic> mutation [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>]. In veterinary
medicine, clinical studies have reported that imatinib mesylate is effective against canine
mast cell tumors carrying the ITD mutation on <italic>c-KIT</italic> in exon 8 or 11 and the
c.1523A&gt;T mutation in exon 9 [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. However,
little is known regarding the clinical response of tumors with other exon 11 mutations to
imatinib mesylate. In particular, deletions and point mutations comprise 20% of canine mast
cell tumor mutations [<xref rid="r6" ref-type="bibr">6</xref>]. We describe 2 novel
<italic>c-KIT</italic> mutations in exon 11 (c.1663-1671del and c.1676T&gt;A) identified in
2 individual cases of canine mast cell tumors that responded favorably to imatinib
mesylate.</p>
    <p>Case 1 was an 11-year-old spayed female mongrel dog weighing 14.1 kg and referred to the
Japan Small Animal Cancer Center with bilateral mandibular lymph node metastases from a mast
cell tumor. The primary tumor on the muzzle had been completely resected by the referring
veterinarian 1 month previously. Initial examination revealed bilateral enlarged mandibular
lymph nodes measuring 2.2 &#xD7; 1.8 &#xD7; 1.5 cm on the left and approximately 1 cm on the right. No
relapse was detected on the muzzle. Cytological examination of the enlarged mandibular lymph
nodes by aspiration biopsy showed metastatic tumor cells. Although chemotherapy was initiated
with concurrent administration of intravenous vinblastine (Exal; Nipponkayaku, Tokyo, Japan)
at 2 mg/m<sup>2</sup> weekly and oral prednisolone (Predonin; Shionogi, Osaka, Japan) at 10&#x2013;15
mg/day, the lymph node lesions progressed rapidly.</p>
    <p>Case 2 was a 10-year-old castrated male Yorkshire terrier weighing 4.7 kg and referred to the
Japan Small Animal Cancer Center with a mast cell tumor metastasis in the right inguinal lymph
node. The primary tumor on the scrotum had been completely resected by the referring
veterinarian 6 months previously. Initial examination revealed enlarged inguinal lymph nodes
measuring 3.0 &#xD7; 4.0 cm on the right with no scrotal relapse detectable. No abnormality was
found on thoracic radiographs. Abdominal radiographs suggested an enlarged internal iliac
lymph node, and abdominal ultrasonography revealed splenomegaly with decreased uniformity of
the splenic echo pattern and confirmed enlargement of both internal and external iliac lymph
nodes. Cytological examination of the enlarged inguinal and internal iliac lymph nodes by
aspiration biopsy showed metastatic tumor cells. Debulking surgery was subsequently performed,
followed by intravenous vinblastine at 2 mg/m<sup>2</sup> and oral prednisolone at 5 mg/day.
However, the inguinal lymph node metastases progressed rapidly. Despite a good clinical
response to 70 mg/m<sup>2</sup> of lomustine (CeeNU; Bristol-Myers Squibb Co., NY, U.S.A.),
this therapy had to be withdrawn due to elevated liver enzymes. Two months following the
initial administration of lomustine, progression of lymph node lesions was detected again.</p>
    <p>Imatinib mesylate (Imatib; Cipla Ltd., Mumbai, India, Glivec Tablets; Novartis Pharma KK,
Tokyo, Japan) was administered orally each day after a meal at an initial dose of 10 mg/kg.
Prednisolone, diphenhydramine and famotidine were administered concomitantly. Although
prednisolone had been administered in both cases for 2 months before imatinib treatment start,
response to the tumors was not observed. Prednisolone was administered at the same dose (Case
1: 10 mg/day, Case 2: 5 mg/day) concurrently with imatinib in order to prevent Darier&#x2019;s sign
and worsening general condition. In Case 1, masitinib (Masivet; AB Science, Paris, France) was
administered orally at 13.3 mg/m<sup>2</sup> after imatinib mesylate proved ineffective.</p>
    <p>Genomic DNA was prepared from tumor cells collected by fine-needle aspiration using DNAzol
Direct (Molecular Research Center Inc., Cincinnati, OH, U.S.A.). To determine the entire
nucleotide sequence of exons, all primers used in the study were designed to be complementary
to the intronic regions flanking the exon. The primers for canine <italic>c-KIT</italic> exon
8, 9 and 11 are as follows: for exon 8, E8F: 5&#x2032;-agccttggtgaggtgttcca-3&#x2032;, E8R:
5&#x2032;-ctaccctgctgtccttccct-3&#x2032;; for exon 9, E9F: 5&#x2032;-atgccaattccaatgtgattgattg-3&#x2032;, E9R:
5&#x2032;-attgatatggcaggcagagc-3&#x2032;; and for exon 11: E11F: 5&#x2032;-catttgttctctaccctaagtgcta-3&#x2032;, E11R:
5&#x2032;-gttccctaaagtcattgttacacg-3&#x2032;. Polymerase chain reaction (PCR) was performed in a total
volume of 20 <italic>&#xB5;l</italic>, containing 1&#xD7; PCR buffer, 2.5 mM deoxynucleotide
triphosphate, 4 <italic>&#xB5;</italic>M each forward and reverse primer and 0.1 unit of Taq
polymerase (TaKaRa Taq<sup>TM</sup> Hot Start Version; Takara Bio Inc., Otsu, Japan). After an
initial denaturation at 95&#xB0;C for 120 sec, 35 cycles of amplification were carried out at 94&#xB0;C
for 30 sec, followed by annealing at 60&#xB0;C for 30 sec and extension at 72&#xB0;C for 30 sec. The PCR
products were separated by electrophoresis on a 4% agarose gel and visualized with EZVision
(Amresco Inc., Solon, OH, U.S.A.). The expected sizes of the PCR products amplified from the
wild-type <italic>c-KIT</italic> for exons 8, 9 and 11 were 228 bp, 330 bp and 277 bp,
respectively. The nucleotide sequence of PCR products was determined by direct sequencing
using an automated DNA sequencer (ABI 3730xI Analyzer; Applied Biosystems, Carlsbad, CA,
U.S.A.). To ensure fidelity of the direct sequencing results, 3 PCR products prepared
separately were sequenced based on the forward and reverse primers used for PCR.</p>
    <p>Clinical response to imatinib mesylate in both cases was evaluated based on the RECIST
guidelines [<xref rid="r10" ref-type="bibr">10</xref>]. The following criteria for antitumor
effect were used: complete remission (CR)=disappearance of all target lesions; partial
remission (PR)=a decrease of &gt;30% in the sums of the longest diameters of target lesions;
progressive disease (PD)=an increase of &gt;20% in the sum of the longest diameters of target
lesions or the appearance of new lesions; and stable disease (SD)=&lt;30% decrease or &lt;20%
increase in the sums of the longest diameters of target lesions. The duration of response was
defined as the interval between the observed PR or CR and a recurrence.</p>
    <p>In Case 1, aberrant bands that may have been derived from the wild-type and mutant
<italic>c-KIT</italic> were detected by PCR analysis of <italic>c-KIT</italic> exon 11
(<xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Polymerase chain reaction amplification products of <italic>c-KIT</italic> exon 11 from
Case 1. Lane M: 50-bp DNA ladder. Lane 1 shows a single band amplified from a normal dog
genome, representing the wild-type <italic>c-KIT</italic>. Lane 2 shows aberrant bands
amplified from Case 1. Although the difference of these bands looks like dozens of
bases, a 9-bp deletion was subsequently identified in sequence analysis. The upper band
may be a heteroduplex of the wild-type and mutant <italic>c-KIT</italic>.</p></caption><graphic xlink:href="jvms-76-545-g001"/></fig>). However, for c-<italic>KIT</italic> exons 8 and 9, a single band from the wild type
was detected. Sequence analysis of the exon 11 amplicon derived from 3 independently amplified
PCR products revealed a 9-bp deletion (c.1663-1671del), corresponding to the deletion of
Gln<sup>555</sup>-Try<sup>556</sup>- Lys<sup>557</sup>(<xref ref-type="fig" rid="fig_002">Fig. 2</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>A: Diagram of KIT domain structure and exon 11 indicating position of mutations in Case
1 and Case 2. Both are located in proximal region of exon 11. Detail mutation of
p.Val559Asp is shown in <xref ref-type="fig" rid="fig_003">Fig. 3</xref>. D1 to D5,
immunoglobulin-like domains; TM, transmembrane domain; JM, juxtamembrane region; TK1,
adenosine triphosphate binding domain; TK2, kinase activation loop. B: Sequence analysis
of the exon 11 amplicon from Case 1. An overlapping curve is seen in the sequencing
result, showing a 9-bp deletion mutation. C: The nucleotide and amino acid sequences of
<italic>c-KIT</italic> exon 11 from Case 1. The 9-bp deletion mutation, located 19
bases downstream of the first codon of exon 11, and the deleted amino acids are
underlined.</p></caption><graphic xlink:href="jvms-76-545-g002"/></fig>). No mutation was found on either exon 8 or exon 9 in this case. As the lesion failed
to respond to vinblastine, imatinib mesylate was used, taking into consideration the
<italic>c-KIT</italic> mutation detected on exon 11. PR and CR were achieved at days 7 and
33 following administration of imatinib mesylate, respectively. Despite ongoing administration
of imatinib mesylate, a relapse of the mast cell tumor was observed in the left mandibular
lymph nodes on day 73. The dosage of imatinib mesylate was therefore increased to 12.7 mg/kg
and continued for 21 days, but the lesion showed no response to treatment. In this case, the
remission duration was 66 days. After imatinib mesylate proved ineffective, masitinib was
administered orally for 24 days; again, no response was observed. A transient response to 70
mg/m<sup>2</sup> of lomustine lasted for 3 months; subsequently, the lesion continued to
grow. The dog succumbed to the progression of mast cell tumor on day 233 after the first
administration of imatinib mesylate.</p>
    <p>In Case 2, a single band corresponding to the size of the wild type was detected by PCR
analysis for <italic>c-KIT</italic> exons 8, 9 and 11. The dog was treated with imatinib
mesylate and achieved CR by day 14. However, a relapse of the mast cell tumor was observed in
the inguinal skin on day 269, and the dog died by progression of mast cell tumor on day 328.
The remission duration in this case was 255 days. Since the mast cell tumor responded to
imatinib mesylate despite the absence of an ITD, the nucleotide sequences of the PCR products
from exons 8, 9 and 11 were examined. The nucleotide sequence obtained from the amplicon of
exon 11 revealed a point mutation (c.1676T&gt;A) corresponding to p.Val559Asp (<xref ref-type="fig" rid="fig_003">Fig. 3</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Fig. 3.</label><caption><p>A: Sequence analysis of the exon 11 amplicon from Case 2. The arrow indicates a point
mutation (c.1676T&gt;A). B: Exon 11 nucleotide and amino acid sequences from Case 2. The
point mutation (c.1676T&gt;A) and the corresponding amino acid substitution
(p.Val559Asp) are underlined and shown by bold letters.</p></caption><graphic xlink:href="jvms-76-545-g003"/></fig>); no mutations were found in either exon 8 or exon 9. These results were confirmed in 3
independently amplified PCR products.</p>
    <p>We identified 2 novel <italic>c-KIT</italic> mutations on exon 11 (c.1663-1671del and
c.1676T&gt;A) in 2 individual cases of canine mast cell tumors and observed that mast cell
tumors with those mutations responded to imatinib mesylate treatment. The 9-bp deletion
mutation caused a loss of 3 amino acids, corresponding to p.Gln555_Lys557del and the point
mutation resulted in the substitution of valine by aspartic acid (p.Val559Asp) in the
juxtamembrane domain of KIT. Previous studies in regard to canine mast cell tumors or
gastrointestinal stromal tumors reported several deletion / insertion mutations
(p.Glu555_Lys557delinsVal, p.Try556_Lys557del, and p.Try556_Val558delinsPhe) in exon 11 [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r6" ref-type="bibr">6</xref>], and amino acids
at 555&#x2013;559 may be in hot spots for gain-of-function mutations [<xref rid="r6" ref-type="bibr">6</xref>]. It has been demonstrated that KIT carrying mutation (p.Glu555_Lys557delinsVal)
caused constitutive ligand-independent phosphorylation which was dependently inhibited by a
selective KIT inhibitor <italic>in vitro</italic> [<xref rid="r6" ref-type="bibr">6</xref>].
Indeed, the lesion of mast cell tumor carrying 9-bp deletion mutation in
<italic>c-KIT</italic> exon 11 became small by treatment with imatinib mesylate in this
study. Therefore, the 9-bp deletion mutation (p.Gln555_Lys557del) may cause constitutive
phosphorylation and be a target for imatinib mesylate. On the other hand, p.Val559Asp which is
the same mutation identified in Case 2 has been identified in human patients with
gastrointestinal stromal tumor [<xref rid="r9" ref-type="bibr">9</xref>], who showed objective
response to imatinib mesylate [<xref rid="r7" ref-type="bibr">7</xref>]. As mentioned above,
Val559 may be in a hot spot of mutation. Then, mast cell tumor lesion in Case 2 responded to
treatment with imatinib mesylate. Taken together, c.1676T&gt;A (p.Val559Asp) may be related to
mast cell tumor growth and be a possible target for imatinib mesylate.</p>
    <p>There is no clear evidence that the 2 novel mutations presented in our study are
gain-of-function mutations for canine mast cell tumors yet. An <italic>in vitro</italic> study
may help clarify this hypothesis. Some cases without a <italic>c-KIT</italic> mutation showed
responsiveness to imatinib mesylate [<xref rid="r3" ref-type="bibr">3</xref>], while many
cases with <italic>c-KIT</italic> mutations also showed a favorable response to imatinib
mesylate [<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. Further research is necessary to better understand the association between each
<italic>c-KIT</italic> mutation and tumor responsiveness to imatinib mesylate.</p>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGMENTS</title>
      <p>We are grateful to all staffs in the Japan Small Animal Medical Center for their assistant
and dedicated nursing of the dogs. This research was supported by a Grant-in-Aid for
Scientific Research (No. 23925032).</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Demetri</surname><given-names>G. D.</given-names></name><name><surname>von Mehren</surname><given-names>M.</given-names></name><name><surname>Blanke</surname><given-names>C. D.</given-names></name><name><surname>Van den Abbeele</surname><given-names>A. D.</given-names></name><name><surname>Eisenberg</surname><given-names>B.</given-names></name><name><surname>Roberts</surname><given-names>P. J.</given-names></name><name><surname>Heinrich</surname><given-names>M. C.</given-names></name><name><surname>Tuveson</surname><given-names>D. A.</given-names></name><name><surname>Singer</surname><given-names>S.</given-names></name><name><surname>Janicek</surname><given-names>M.</given-names></name><name><surname>Fletcher</surname><given-names>J. A.</given-names></name><name><surname>Silverman</surname><given-names>S. G.</given-names></name><name><surname>Silberman</surname><given-names>S. L.</given-names></name><name><surname>Capdeville</surname><given-names>R.</given-names></name><name><surname>Kiese</surname><given-names>B.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Dimitrijevic</surname><given-names>S.</given-names></name><name><surname>Druker</surname><given-names>B. J.</given-names></name><name><surname>Corless</surname><given-names>C.</given-names></name><name><surname>Fletcher</surname><given-names>C. D.</given-names></name><name><surname>Joensuu</surname><given-names>H.</given-names></name></person-group><year>2002</year>
<article-title>Efficacy and safety of imatinib mesylate
in advanced gastrointestinal stromal tumors</article-title>. <source><italic>N. Engl. J.
Med.</italic></source><volume>347</volume>: <fpage>472</fpage>&#x2013;<lpage>480</lpage>.
doi: <pub-id pub-id-type="doi">10.1056/NEJMoa020461</pub-id><pub-id pub-id-type="pmid">12181401</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Druker</surname><given-names>B. J.</given-names></name><name><surname>Talpaz</surname><given-names>M.</given-names></name><name><surname>Resta</surname><given-names>D. J.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Buchdunger</surname><given-names>E.</given-names></name><name><surname>Ford</surname><given-names>J. M.</given-names></name><name><surname>Lydon</surname><given-names>N. B.</given-names></name><name><surname>Kantarjian</surname><given-names>H.</given-names></name><name><surname>Capdeville</surname><given-names>R.</given-names></name><name><surname>Ohno-Jones</surname><given-names>S.</given-names></name><name><surname>Sawyers</surname><given-names>C. L.</given-names></name></person-group><year>2001</year>
<article-title>Efficacy and safety of a specific
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</article-title>.
<source><italic>N. Engl. J. Med.</italic></source><volume>344</volume>:
<fpage>1031</fpage>&#x2013;<lpage>1037</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM200104053441401</pub-id><pub-id pub-id-type="pmid">11287972</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Isotani</surname><given-names>M.</given-names></name><name><surname>Ishida</surname><given-names>N.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Yagihara</surname><given-names>H.</given-names></name><name><surname>Ochi</surname><given-names>S.</given-names></name><name><surname>Kato</surname><given-names>R.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Fujita</surname><given-names>M.</given-names></name><name><surname>Fujino</surname><given-names>Y.</given-names></name><name><surname>Setoguchi</surname><given-names>A.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2008</year>
<article-title>Effect of tyrosine kinase inhibition by
imatinib mesylate on mast cell tumors in dogs</article-title>. <source><italic>J. Vet.
Intern. Med.</italic></source><volume>22</volume>:
<fpage>985</fpage>&#x2013;<lpage>988</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2008.00132.x</pub-id><pub-id pub-id-type="pmid">18564222</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Kuroki</surname><given-names>S.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Yasuda</surname><given-names>A.</given-names></name><name><surname>Sawada</surname><given-names>H.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2013</year>
<article-title>Imatinib-associated tumour response in a
dog with a non-resectable gastrointestinal stromal tumour harbouring a
<italic>c-kit</italic> exon 11 deletion mutation</article-title>. <source><italic>Vet.
J.</italic></source><volume>198</volume>: <fpage>271</fpage>&#x2013;<lpage>274</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tvjl.2013.05.035</pub-id><pub-id pub-id-type="pmid">23820134</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Sugisaki</surname><given-names>O.</given-names></name><name><surname>Ishii</surname><given-names>N.</given-names></name><name><surname>Yamada</surname><given-names>O.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Kuroki</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>Y.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2012</year>
<article-title>Canine intestinal mast cell tumor with
c-kit exon 8 mutation responsive to imatinib therapy</article-title>.
<source><italic>Vet. J.</italic></source><volume>193</volume>:
<fpage>264</fpage>&#x2013;<lpage>267</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tvjl.2011.10.027</pub-id><pub-id pub-id-type="pmid">22153896</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Letard</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hanssens</surname><given-names>K.</given-names></name><name><surname>Palmerini</surname><given-names>F.</given-names></name><name><surname>Leventhal</surname><given-names>P. S.</given-names></name><name><surname>Guery</surname><given-names>S.</given-names></name><name><surname>Moussy</surname><given-names>A.</given-names></name><name><surname>Kinet</surname><given-names>J. P.</given-names></name><name><surname>Hermine</surname><given-names>O.</given-names></name><name><surname>Dubreuil</surname><given-names>P.</given-names></name></person-group><year>2008</year>
<article-title>Gain-of-function mutations in the
extracellular domain of KIT are common in canine mast cell tumors</article-title>.
<source><italic>Mol. Cancer Res.</italic></source><volume>6</volume>:
<fpage>1137</fpage>&#x2013;<lpage>1145</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0067</pub-id><pub-id pub-id-type="pmid">18644978</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Lim</surname><given-names>K. H.</given-names></name><name><surname>Huang</surname><given-names>M. J.</given-names></name><name><surname>Chen</surname><given-names>L. T.</given-names></name><name><surname>Wang</surname><given-names>T. W.</given-names></name><name><surname>Liu</surname><given-names>C. L.</given-names></name><name><surname>Chang</surname><given-names>C. S.</given-names></name><name><surname>Liu</surname><given-names>M. C.</given-names></name><name><surname>Hsieh</surname><given-names>R. K.</given-names></name><name><surname>Tzen</surname><given-names>C. Y.</given-names></name></person-group><year>2008</year>
<article-title>Molecular analysis of secondary kinase
mutations in imatinib-resistant gastrointestinal stromal tumors</article-title>.
<source><italic>Med. Oncol.</italic></source><volume>25</volume>:
<fpage>207</fpage>&#x2013;<lpage>213</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12032-007-9014-2</pub-id><pub-id pub-id-type="pmid">18488160</pub-id></mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Longley</surname><given-names>B. J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Blount</surname><given-names>J. L.</given-names></name><name><surname>Langley</surname><given-names>K.</given-names></name><name><surname>Caughey</surname><given-names>G. H.</given-names></name></person-group><year>1999</year>
<article-title>Clustering of activating mutations in
c-KIT&#x2019;s juxtamembrane coding region in canine mast cell neoplasms</article-title>.
<source><italic>J. Invest. Dermatol.</italic></source><volume>112</volume>:
<fpage>165</fpage>&#x2013;<lpage>170</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1523-1747.1999.00488.x</pub-id><pub-id pub-id-type="pmid">9989791</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Tan</surname><given-names>C. B.</given-names></name><name><surname>Zhi</surname><given-names>W.</given-names></name><name><surname>Shahzad</surname><given-names>G.</given-names></name><name><surname>Mustacchia</surname><given-names>P.</given-names></name></person-group><year>2012</year>
<article-title>Gastrointestinal stromal tumors: a review
of case reports, diagnosis, treatment, and future directions</article-title>.
<source><italic>ISRN Gastroenterol.</italic></source><volume>2012</volume>:
<fpage>595968</fpage>. doi: <pub-id pub-id-type="doi">10.5402/2012/595968</pub-id><pub-id pub-id-type="pmid">22577569</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Therasse</surname><given-names>P.</given-names></name><name><surname>Arbuck</surname><given-names>S. G.</given-names></name><name><surname>Eisenhauer</surname><given-names>E. A.</given-names></name><name><surname>Wanders</surname><given-names>J.</given-names></name><name><surname>Kaplan</surname><given-names>R. S.</given-names></name><name><surname>Rubinstein</surname><given-names>L.</given-names></name><name><surname>Verweij</surname><given-names>J.</given-names></name><name><surname>Van Glabbeke</surname><given-names>M.</given-names></name><name><surname>van Oosterom</surname><given-names>A. T.</given-names></name><name><surname>Christian</surname><given-names>M. C.</given-names></name><name><surname>Gwyther</surname><given-names>S. G.</given-names></name></person-group><year>2000</year>
<article-title>New guidelines to evaluate the response
to treatment in solid tumors. European Organization for Research and Treatment of
Cancer, National Cancer Institute of the United States, National Cancer Institute of
Canada</article-title>. <source><italic>J. Natl. Cancer
Inst.</italic></source><volume>92</volume>: <fpage>205</fpage>&#x2013;<lpage>216</lpage>. doi:
<pub-id pub-id-type="doi">10.1093/jnci/92.3.205</pub-id><pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Yamada</surname><given-names>O.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Sugisaki</surname><given-names>O.</given-names></name><name><surname>Ishii</surname><given-names>N.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Kuroki</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>Y.</given-names></name><name><surname>Isotani</surname><given-names>M.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2011</year>
<article-title>Imatinib elicited a favorable response in
a dog with a mast cell tumor carrying a c-kit c.1523A&gt;T mutation via suppression of
constitutive KIT activation</article-title>. <source><italic>Vet. Immunol.
Immunopathol.</italic></source><volume>142</volume>:
<fpage>101</fpage>&#x2013;<lpage>106</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2011.04.002</pub-id><pub-id pub-id-type="pmid">21561667</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
